Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468189 | 1.00 | ITK (0.46) | ITKHTR2AFADS1PDPK1JAK2 | |
| SCHEMBL30548016 | 0.84 | MAP2K4 (0.56) | ITKHTR2APDPK1JAK2MAP2K4 | |
| SCHEMBL11904268 | 0.84 | MAP2K4 (0.56) | ITKHTR2APDPK1JAK2MAP2K4 | |
| SCHEMBL31391692 | 0.80 | CYP1A2 (0.44) | PDPK1JAK2DCLK1PRKD3MAP4K4 | |
| SCHEMBL30855645 | 0.79 | PDPK1 (0.68) | HTR2AFADS1PDPK1JAK2METAP2 | |
| SCHEMBL14095607 | 0.79 | ITK (0.49) | ITKHTR2AFADS1PDPK1JAK2 | |
| SCHEMBL785649 | 0.78 | JAK2 (0.60) | ITKHTR2AFADS1PDPK1JAK2 | |
| SCHEMBL23901370 | 0.77 | NTRK1 (0.64) | AURKB | |
| SCHEMBL1553551 | 0.76 | ITK (0.46) | ITKHTR2AFADS1MAP2K4METAP2 | |
| SCHEMBL25475378 | 0.76 | FADS1 (0.51) | ITKHTR2AFADS1MAP2K4METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
| CN-116568684-A | Novel compounds | AC免疫有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-9884043-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170340610-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| EP-2683693-B1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
| US-9095583-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| EP-2487159-A1 | RorgammaT inhibitors | MSD Oss B.V. (NL) | 2012-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | ITK 4445/4885HTR2A 4218/4885FADS1 3478/4885 |
| US-20170340610-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | ITK 3447/4885HTR2A 4133/4885FADS1 3797/4885 |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, FSHR | ITK 4233/4885HTR2A 337/4885FADS1 504/4885 |
| US-20140038942-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | ITK 3447/4885HTR2A 4133/4885FADS1 3797/4885 |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | ITK 1482/4885HTR2A 4448/4885FADS1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.